Full title: SarcoSIGHT: A Randomised-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
Age: Any
Phase: Other
Locations:
Manchester –Manchester University Hospitals NHS Foundation Trust
Owestry – The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust
Birmingham – The Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham Women’s and Children’s NHS Foundation Trust
London – The Royal National Orthopaedic Hospital NHS Trust, The Royal Marsden NHS Foundation Trust
Oxford – Oxford University Hospitals NHS Foundation Trust
Leeds – The Leeds Teaching Hospitals NHS Trust
Nottingham –Nottingham University Hospitals NHS Trust
Bristol – North Bristol NHS Trust
Plymouth – University Hospitals Plymouth NHS Trust
Devon – Royal Devon University Healthcare NHS Foundation Trust
Manchester – The Christie NHS Foundation Trust
Swansea – Swansea Bay University Health Board
Lancashire – Lancashire Teaching Hospitals NHS Foundation Trust
Aberdeen – NHS Grampian
Edinburgh – NHS Lothian
Glasgow – NHS Greater Glasgow and Clyde
Belfast – Belfast Health and Social Care Trust, South Eastern Health and Social Care Trust
Brief summary:
A prospective, 2-arm, open-label, UK multi-centre, randomised control trial comparing fluorescence-guided surgery (FGS) with indocyanine green (ICG) to standard care (no fluorescence guidance) to determine the effect on the unexpected positive margin rate (UPM) in patients with sarcoma.
The aims of the trial are to find out:
- whether fluorescence guided surgery is better than standard surgery to remove the sarcoma with a clear margin
- whether there are fewer complications with fluorescence guided surgery
- how both surgeries affect quality of life
To find out more about this trial and whether you could take part, talk to your clinical team.